Cargando…
P1160: RESULTS OF A PHASE 2 EXPANDED ACCESS STUDY OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
Autores principales: | Castillo, J. J., Kingsley, E. C., Narang, M., Yimer, H. A., Dasanu, C. A., Melear, J. M., Coleman, M., Farber, C. M., Gupta, M., Shulman, J., Mantovani, E. H., Zhang, X., Cohen, A., Huang, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431198/ http://dx.doi.org/10.1097/01.HS9.0000847508.16968.e7 |
Ejemplares similares
-
Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States
por: Castillo, Jorge J, et al.
Publicado: (2023) -
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
por: Deshpande, Anagha, et al.
Publicado: (2022) -
Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
por: Muñoz, Javier, et al.
Publicado: (2022) -
Cutaneous macroglobulinosis with Waldenström macroglobulinemia
por: Hassab-El-Naby, Hussein M.M., et al.
Publicado: (2020) -
Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
por: Dogliotti, Irene, et al.
Publicado: (2022)